Leronlimab

Generic Name: Leronlimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 674782-26-4

Unique Ingredient Identifier: Y1J4NP8FF0

Background: Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn. It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.

Indication: Leronlimab is currently being investigated for the treatment of a number of cancers and HIV.

Recently leronlimab has begun a phase II clinical trial in severely ill COVID-19 patients. Preliminary data shows a reduction in the 'cytokine storm', particularly IL-6, as well as a normalization of the CD4/CD8 T-cell ratio. These results may mitigate immune mediate injury seen in severely ill COVID-19 patients.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial

CytoDyn engages Syneos Health as CRO for Phase II oncology trial evaluating leronlimab in relapsed/refractory micro-satellite stable colorectal cancer, with patient screening expected to start in early 2025.

cytodyn.com

3 months ago

CytoDyn Announces Preliminary Findings in Study with SMC Laboratories

CytoDyn announces preliminary findings from preclinical study with SMC Laboratories, showing leronlimab's significant fibrosis reversal and potential synergies with Resmetirom in MASH treatment.

stocktitan.net

3 months ago

September 2024 Letter to Shareholders

CytoDyn Inc. (CYDY) reports significant 2024 progress, including FDA lifting leronlimab's clinical hold, submitting two trial protocols, settling with Amarex for $10 million, and initiating pre-clinical/clinical trials. Focus areas include oncology (colorectal cancer, triple-negative breast cancer, glioblastoma) and inflammation (HIV-related chronic inflammation, Alzheimer's Disease, chronic fatigue syndrome). The company believes it has sufficient cash to advance development into 2025.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy